9-Hydroxy-5,7,11,14-eicosatetraenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 9-Hydroxy-5,7,11,14-eicosatetraenoic acid
• 英文别名: (5E,7E,11E,14E)-9-hydroxyicosa-5,7,11,14-tetraenoic acid
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: KATOYYZUTNAWSA-MCQBKTFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-Hydroxy-5,7,11,14-eicosatetraenoic acid 、 重氮甲烷 生成 methyl (5E,7E,11E,14E)-9-hydroxyicosa-5,7,11,14-tetraenoate
  参考文献：
  名称：

  HAWKINS, DAN J.;KUHN, HARTMUT;PETTY, ERIC H.;BRASH, ALAN R., ANAL. BIOCHEM., 173,(1988) N 2, C. 456-462

  摘要：

  DOI：

文献信息

• Myeloperoxidase, a risk indicator for cardiovascular disease
  申请人：——

  公开号：US20020164662A1

  公开（公告）日：2002-11-07

  Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.

  用于确定个人罹患或患有心血管疾病风险的诊断测试。在一个实施方案中，本诊断测试包括确定从个体或测试对象处获取的身体样本中髓过氧化物酶（MPO）活性的水平。在另一个实施方案中，诊断检测包括确定从测试对象处获取的身体样本中 MPO 质量的水平。在另一个实施方案中，诊断检测包括确定从测试对象处获取的身体样本中一种或多种选择性 MPO 生成的氧化产物的水平。选择性 MPO 生成的氧化产物是指二酪氨酸、硝基酪氨酸、蛋氨酸亚砜或 MPO 生成的脂质过氧化产物。然后，将测试对象身体样本中的 MPO 活性、MPO 质量或所选 MPO 生成的氧化产物的水平与一个预定值进行比较，该预定值是通过测量从普通人群或特定人群中获得的可比身体样本中的 MPO 活性、MPO 质量或所选 MPO 生成的氧化产物而得出的。通过这种比较可以确定受试者患心血管疾病的风险。
• Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
  申请人：The Cleveland Clinic Foundation

  公开号：US20030180218A1

  公开（公告）日：2003-09-25

  A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of therapeutic agents comprises determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at base line or following administration of the therapeutic agent. The marker includes at least one of MPO activity, MPO mass, select MPO-generated oxidation products, and combinations thereof. The level of the systemic marker is compared with a predetermined value to monitor the anti-inflammatory and/or antioxidant actions of the therapeutic agent.

  一种监测治疗剂的抗炎和/或抗氧化作用的诊断方法包括确定在基线或服用治疗剂后从受试者体内采集的样本中至少一种指示炎症或氧化的全身标记物的水平。标记物包括 MPO 活性、MPO 质量、MPO 生成的特定氧化产物及其组合中的至少一种。将全身标记物的水平与预定值进行比较，以监测治疗剂的抗炎和/或抗氧化作用。
• Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities
  申请人：——

  公开号：US20040132820A1

  公开（公告）日：2004-07-08

  The present invention relates to the use of the antiviral activity of exogenous leukotriene B 4 (LTB 4 ), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal viruses. The present invention also relates to the use of LTB 4 as an anti-neoplastic agent in the prophylaxis and treatment of cancers induced by tumor viruses and in other neoplasic diseases. The human and animal viruses are DNA viruses, such as parvoviridae, papovaviridae, adenoviridae, herpesviridae, poxyviridae and hepadnaviridae; RNA viruses, such as picornaviridae, togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, and filoviridae in general, and Retroviridae such as HIV-1 and HIV-2.

  本发明涉及利用外源性白三烯 B 4 (LTB 4 )、其变体和衍生物的抗病毒活性作为人类和动物病毒引起的病毒感染的治疗剂。本发明还涉及使用 LTB 4 作为抗肿瘤剂，用于预防和治疗由肿瘤病毒诱发的癌症和其他肿瘤性疾病。人类和动物病毒包括 DNA 病毒，如副病毒科、乳头瘤病毒科、腺病毒科、疱疹病毒科、poxyviridae 和 hepadnaviridae；RNA 病毒，如 picornaviridae、togaviridae、orthomyxoviridae、paramyxoviridae、coronaviridae、reoviridae 和 filoviridae，以及逆转录病毒科，如 HIV-1 和 HIV-2。
• In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
  申请人：Gosselin Jean

  公开号：US20050239889A1

  公开（公告）日：2005-10-27

  The invention relates to the in vivo release of endogenous anti-microbial mediators using leukotriene B4 administration. The present invention furthermore relates to the use of leukotriene B4 for the treatment and/or prophylaxis of diseases that are positively influenced by such anti-microbial mediators.

  本发明涉及使用白三烯 B4 在体内释放内源性抗微生物介质。本发明还涉及使用白三烯 B4 治疗和/或预防受此类抗微生物介质积极影响的疾病。
• USE OF LEUKOTRIENE B 4? OR ITS ANALOGUES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS
  申请人：Virocell Inc.

  公开号：EP0881900A1

  公开（公告）日：1998-12-09